14 results about "Human growth hormone" patented technology

This invention relates to treating Prader-Willi Syndrome (PWS) using a KATP channel opener. The channel opener may be coadministered with other therapies used to treat PWS, such as human growth hormone, a wakefulness promoting agent, or a psychiatric or mood stabilizing drug, thereby allowing the baseline dosages of these other therapies to be decreased or making these other therapies unnecessary. The invention also relates to treating PWS based on the PWS nutritional phase of a patient, to prevent the patient's PWS nutritional phase from progressing or shift the patient's PWS nutritional phase back to an earlier phase. The invention further relates to treating PWS, and conditions associated with low basal metabolic rate or hyperphagia, with the KATP channel opener based on a patient's blood ketone levels.

The invention relates to the technical field of biological medicine, in particular to polypeptide for promoting release of growth hormone and application of the polypeptide, the polypeptide is shown as a formula (I), and in addition, the invention further provides application of the polypeptide shown as the formula (I) in preparation of medicine for diagnosing and / or treating diseases related to human growth hormone deficiency. Formula (I)

This invention provides single-domain antibodies or antigen-binding fragments thereof that specifically bind to growth hormone (e.g., human growth hormone), polypeptide constructs and conjugates containing said single-domain antibodies or antigen-binding fragments thereof, nucleic acid molecules encoding said single-domain antibodies or antigen-binding fragments thereof, and host cells containing them, as well as related uses. Furthermore, it provides uses of said single-domain antibodies or antigen-binding fragments thereof, polypeptide constructs, or conjugates for the purification and / or detection of growth hormone (e.g., human growth hormone).

The invention belongs to the technical field of biological medicine and nano-drug delivery, and particularly relates to a long-acting growth hormone (hGH) wrapped bacterial outer membrane vesicle and application, and the outer membrane vesicle GH-OMVs wraps a human growth hormone mutant with an amino acid sequence shown as SEQ ID NO: 1. The GH-OMVs provided by the invention can be used for preparing medicines or preparations for preventing and / or treating diseases related to growth hormone deficiency or growth hormone-related metabolic disorder, including but not limited to growth hormone deficiency, dwarf / low height, osteoporosis and the like, and has a good clinical application prospect.

The present application relates to a kind of Fc mutant, fusion protein, nucleic acid molecule, expression vector, recombinant cell, pharmaceutical composition and its purposes.Fc mutant has the amino acid sequence as any one of SEQ ID NO:3~7;Fusion protein includes: second peptide segment, second peptide segment is the functional region of bioactive molecule, third peptide segment, third peptide segment includes the amino acid sequence shown in SEQ ID NO:2 or the Fc mutant of preceding, second peptide segment is connected with third peptide segment.The Fc mutant of the present application is monomer form, fusion protein has higher in vitro and in vivo activity and lower ADCC, CDC effect, can effectively treat growth hormone deficiency.

The invention provides a novel nano antibody-based recombinant long-acting human growth hormone fusion protein, nucleic acid, a pharmaceutical composition, application and the like. Existing long-acting means of PEGylation, Fc fusion and the like often cause reduction of activity, the human growth hormone is innovatively fused with an anti-albumin nano antibody with a specific sequence, and protein with larger molecules is formed through combination of the nano antibody and albumin antigen, so that the half-life period of the human growth hormone is prolonged, the activity of the human growth hormone is prolonged, and the human growth hormone can be used for preparing the anti-albumin nano antibody. In addition, the activity of the fusion protein provided by the invention is higher than that of a human growth hormone standard substance. The fusion protein and the like have wide industrial application prospects in the field of biological medicines.

The invention discloses an affinity chromatography method for purifying human growth hormone and a DARPin dimer ligand. The DARPin dimer comprises a first DARPin monomer and a second DARPin monomer which are connected through a connecting peptide or a disulfide bond; each DARPin monomer is provided with a four-section type structure of an N-cap, a first internal repeated module IR1, a second internal repeated module IR2 and a C-cap; the amino acid sequence of the DARPin monomer is selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 or SEQ ID NO: 5 in a sequence list, and the amino acid sequence of the DARPin monomer has 90%-98% sequence identity with any amino acid sequence selected from the list. According to the present invention, through the design of the DARPin dimer ligand having the N-cap, the first internal repeating module IR1, the second internal repeating module IR2 and the C-cap four-segment structure, and the directed random mutation of the IR1 / IR2 region, the novel ligand having high affinity and high specificity on the human growth hormone is obtained, and the non-specific binding of the host protein and the structure-similar impurities is significantly reduced;

A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4 / CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

The invention relates to the technical field of biological medicine, in particular to a recombinant human growth hormone injection preparation and application thereof. The recombinant human growth hormone injection preparation provided by the invention has the advantages that the pH value is close to the human physiological pH value, the stability is good, the activity is high, byproducts such as endogenous toxins are few, the transportation and the storage are convenient, and the clinical use is more convenient, easier and safer; in addition, the recombinant human growth hormone injection preparation is simple in preparation method and has important market popularization value.

Described herein are growth hormone receptor antagonists and modified growth hormone receptor antagonists. The growth hormone receptor antagonists and the modified growth hormone receptor antagonists are useful in the treatment of diseases or conditions responsive to human growth hormone receptor antagonists, such as cancer and acra hypertrophy.

This invention relates to the field of biomedical technology, and more particularly to a polypeptide that promotes the release of growth hormone and its applications, said polypeptide being as shown in formula (I). Furthermore, the application of the polypeptide shown in formula (I) in the preparation of medicaments for diagnosing and / or treating diseases related to human growth hormone deficiency is also provided. Formula (I).

This invention discloses a recombinant human growth hormone-collagen fusion protein, its preparation method, and its applications, relating to the field of fusion protein technology. The fusion protein comprises a human growth hormone sequence and a human-like collagen sequence. The amino acid sequence of the fusion protein is shown in SEQ ID NO.7. The first homologous region of the human growth hormone is located at the N-terminus of the fusion protein, and the second homologous region of the human-like collagen is located at the C-terminus. In this invention, recombinant human growth hormone and human collagen with tissue repair function are fused through genetic engineering, achieving efficient expression in the periplasmic space in *E. coli*. High-purity products are obtained by GH affinity chromatography and weak cation exchange chromatography. The protein has a normal structure and good in vitro activity, and can be used to prepare long-acting growth hormone preparations or wound repair materials, showing significant clinical application prospects.

The application discloses a kind of recombinant cyclic human growth hormone-Fc fusion protein and application thereof.The fusion protein is sequentially connected by Fc fragment, human growth hormone, Fc fragment from N-terminal to C-terminal using two connection peptides to form a molecule, and forms a pair or more pairs of disulfide bond or does not form disulfide bond after the folding of two Fc fragments, to constitute cyclic Fc-hGH-Fc.The refolding ratio of the cyclic Fc-hGH-Fc fusion protein is higher than the yield of monomer Fc / Fc-hGH expression refolding, and the form of Fc / Fc homodimer and double body hGH-Fc / hGH-Fc is less, which is convenient for later purification.The fermentation preparation process of the fusion protein of the application is simple, convenient for purification, high in yield and low in cost.The fusion protein of the application weakens the protein clearance effect caused by growth hormone receptor by using the steric hindrance effect of Fc, further prolongs the half-life of drug and increases the efficacy.

Cranial placodes are embryonic structures essential for sensory and endocrine organ development. The efficient derivation of cranial placodes from human pluripotent stem cells is disclosed where the timed removal of the BMP inhibitor Noggin, a component of the dual-SMAD inhibition strategy of neural induction, triggers placode induction at the expense of CNS fates. Further fate specification at the pre-placode stage enables the selective generation of placode-derived trigeminal ganglia capable of in vivo engraftment, mature lens fibers and anterior pituitary hormone-producing cells that upon transplantation produce hormones including, but not limited to, human growth hormone and adrenocortiocotropic hormone in vivo. Alternatively, anterior pituitary hormone-producing cells are generated in cell culture systems in vitro.